HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

HC Wainwright reaffirmed their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $75.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q1 2025 earnings at $2.45 EPS and Q4 2025 earnings at $2.85 EPS.

Several other brokerages have also weighed in on SRPT. Guggenheim upped their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Piper Sandler dropped their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Finally, Robert W. Baird cut their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Stock Up 0.4 %

Sarepta Therapeutics stock opened at $119.33 on Wednesday. The company has a market capitalization of $11.40 billion, a PE ratio of 95.46 and a beta of 0.77. Sarepta Therapeutics has a 12-month low of $102.15 and a 12-month high of $173.25. The firm’s fifty day moving average is $121.75 and its 200 day moving average is $130.06. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Large investors have recently bought and sold shares of the company. Smith Salley Wealth Management purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at $889,000. Park Avenue Securities LLC purchased a new stake in Sarepta Therapeutics during the fourth quarter valued at about $205,000. Harbor Capital Advisors Inc. lifted its holdings in Sarepta Therapeutics by 33.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,706 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 427 shares during the last quarter. ORG Partners LLC boosted its position in Sarepta Therapeutics by 17.6% during the fourth quarter. ORG Partners LLC now owns 2,000 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 300 shares during the period. Finally, Nordea Investment Management AB increased its stake in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock worth $8,228,000 after purchasing an additional 10,815 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.